Merge eFilm achieves record revenues

Article

Financial results for the third quarter, ended Sept. 30, at Merge eFilm showed a 44% increase in revenue over the year earlier period: $7.6 million compared with $5.3 million. Revenues were $20.2 million for the nine months ended Sept. 30, also an

Financial results for the third quarter, ended Sept. 30, at Merge eFilm showed a 44% increase in revenue over the year earlier period: $7.6 million compared with $5.3 million. Revenues were $20.2 million for the nine months ended Sept. 30, also an increase of 44% over the previous nine-month period. Net income for the quarter rose 55% to $1.6 million. Net income for the nine months increased 85% to $4.3 million. Results include approximately two and a half months of revenues from RIS Logic. The RIS Logic acquisition completed in late July strengthened Merge eFilm's product portfolio to include a full RIS/PACS solution. It also enhanced target market positioning and accelerated the effectiveness of operations, according to Richard A. Linden, Merge eFilm president and CEO.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.